Background-Ischemia/reperfusion injury may have deleterious short-and long-term consequences for cardiac allografts.
R estoration of compromised blood flow is vital in vascular occlusion, but paradoxically, tissue reperfusion is often accompanied by significant morbidity and mortality. This is especially evident in heart transplantation in which ischemia/ reperfusion injury (IRI) may result in primary graft failure and the development of untreatable chronic rejection. [1] [2] [3] Clinically feasible organ preservation strategies are needed to limit early IRI, to blunt subsequent pathological immunological and tissue remodeling responses, and to prolong cardiac allograft recipient survival.
Clinical Perspective on p 1150
Endothelial cell (EC) dysfunction is a hallmark of IRI 4 -6 and the development of cardiac allograft fibrosis and arteriosclerosis, manifestations of chronic rejection. 2,3,7 IRI 5 and several IRIrelated factors such as hypoxia, thrombin, vascular endothelial growth factor, and RhoA GTPase activation are involved in EC-EC gap formation and compromised endothelial stability. 6,8 -10 Dysfunctional ECs also predispose the patients to thrombosis, leukocyte adhesion, and vasoconstriction and are involved in pathological fibroproliferation. 3, 7, 11 They also directly participate in myocardial fibrosis through endothelial-tomesenchymal transition (EndMT) in which transforming growth factor (TGF)-␤1 induces EC transdifferentiation to fibroblasts. 11 Pericytes are perivascular cells that cover endothelial tubes in small arterioles, capillaries, and postcapillary venules.
Pericytes communicate with the underlying ECs, share the same basement membrane, and regulate the microvascular tone 12 possibly mediated by RhoA GTPase activation. 13, 14 Pericyte dysfunction may result in microvascular hypertension, pathological angiogenesis, increased capillary permeability, 12 and the no-reflow phenomenon after IRI. 15 Statins are cholesterol-lowering drugs that are widely used in preventing cardiovascular diseases. 16 They also have important cholesterol-independent vasculoprotective effects mediated largely through the inhibition of Rho GTPases, important regulators of cell cytoskeleton and intracellular signaling pathways. 16, 17 Simvastatin is commonly begun shortly after heart transplantation because of its beneficial effects against chronic rejection and on long-term survival. 18, 19 Here, we investigated whether peroral simvastatin treatment of rat cardiac allograft donors 2 hours before allograft procurement has vasculoprotective and immunomodulatory effects on IRI and subsequent pathological tissue remodeling.
Methods

Experimental Design
Cardiac allografts were transplanted from fully major histocompatibility complex-mismatched male Dark Agouti (DA; RT1 av1 ) to male Wistar Furth (RT1 u ) rats (Scanburg, Stockholm, Sweden). Allografts were left without hypothermic preservation or were preserved in PBS at 4°C for 2 to 4 hours, depending on the study model. Warm ischemia was standardized to 1 hour. Microvascular RhoA activity and intragraft inflammation were analyzed by immunohistochemistry and immunofluorescence; microvascular interendothelial gaps, by biotinylated Ricinus communis lectin and transmission electron microscopy; microvascular leakage, by a modified Miles Assay; perfusion, by laser Doppler monitoring and intracoronary FITC-labeled Lycopersicon esculentum (Tomato) lectin; myocardial edema, by magnetic resonance imaging; and myocardial injury, by serum cardiac troponin T. Intragraft mRNA expression was determined by real-time reverse-transcription polymerase chain reaction. In the chronic rejection model, fibrosis was analyzed by Masson trichrome staining, and arteriosclerosis was assessed morphometrically by hematoxylin-eosin and Resorcin-Fuchsin staining for internal elastic lamina. To prevent severe episodes of acute rejection, allograft recipients were given cyclosporine A (Novartis, Basel, Switzerland) 2.0 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 SC for the first 7 days and 1.0 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 thereafter. Sample sizes are given in the figure legends. The Methods section in the online-only Data Supplement gives detailed information.
Drug Administration
Peroral simvastatin (Merck Research Laboratories, Whitehouse Station, NJ) was given to the donor as a single dose (5 mg/kg) 2 hours before graft removal, to the recipient (2 mg/kg) 2 hours before reperfusion and daily thereafter (2 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 ), or to both. The controls received polyethylene glycol vehicle orally. To inhibit nitric oxide synthase (NOS) activity, donors received N-nitro-L-arginine methyl ester (L-NAME; Sigma-Aldrich Co, St. Louis, MO) 50 mg ⅐ kg Ϫ1 ⅐ d Ϫ1 for 4 days before allograft removal. To block heme oxygenase-1 (HO-1) activity, zinc protoporphyrin (Porphyrin Products Inc, Logan, UT) was administered intraperitoneally (20 mg/kg) to donor rats 2 hours before allograft removal. To supplement RhoA GTPase prenylation pathway, geranylgeranyl pyrophosphate (Sigma-Aldrich) at a concentration of Ϸ1 mg/mL in methanol was administered intraperitoneally (1 mg/kg) to donor rats 2 hours before allograft removal.
Effects of Simvastatin on Transforming Growth Factor-␤1-Induced Endothelial-to-Mesenchymal Transition In Vitro
Transforming growth factor-␤1 10 ng/mL was used to induce EndMT in human cardiac microvascular ECs. Simvastatin was dissolved in EtOH and activated by NaOH followed by neutralization, and concentrations of 0.1, 0.5, and 1.0 mol/L were used to inhibit EndMT. Immunohistochemistry identified endothelial CD31 and zonula occludens-1 density. Real-time reverse-transcription polymerase chain reaction analysis, SDS-PAGE, and immunoblotting were performed to measure the mRNA expression and protein levels of the mesenchymal markers calponin and ␣-smooth muscle actin (␣-SMA). 
Statistics
Results
Microvascular Endothelial Cells and Pericytes Express HMG-CoA Reductase in the Rat Heart
To identify the target cells of donor simvastatin treatment, we performed HMG-CoA reductase immunostainings in normal DA rat hearts. HMG-CoA reductase immunoreactivity was found mainly in cardiac vasculature ( Figure 1A ). Immunofluorescent double stainings showed that HMG-CoA reductase was expressed mostly in microvascular rat endothelial cell antigen-1 ϩ (RECA-1 ϩ ) ECs and in NG2 ϩ pericytes but not in ␣-SMA ϩ smooth muscle cells or in tropomyosin ϩ cardiomyocytes ( Figure 1A ).
Cold and Warm Ischemia Induce Microvascular Endothelial Cell and Pericyte RhoA/ROCK Activation and Endothelial Cell-Endothelial Cell Gap Formation
To determine whether cold and warm ischemia lead to RhoA/ ROCK activation, we performed immunostainings of adducin phosphorylated at Thr445 (p-adducin) 20, 21 in normal DA hearts and hearts subjected to 4-hour cold or to 4-hour cold and 1-hour warm ischemia. Microvascular p-adducin immunoreactivity was low in normal DA hearts ( Figure 1B through D), whereas 4-hour cold and 1-hour warm ischemia resulted in prominent p-adducin immunoreactivity in capillaries (PϽ0.05; Figure 1B ), postcapillary venules, arterioles ( Figure 1C ), and arteries (PϽ0.05; Figure  1D ). P-adducin immunoreactivity localized to some RECA-1 ϩ capillary ECs but mainly to NG2 ϩ pericytes and to ␣-SMA ϩ smooth muscle cells in postcapillary venules and arteries ( Figure  1B through 1D).
Transmission electron microscope analysis indicated that combined 4-hour cold and 1-hour warm ischemia markedly increased the incidence of microvascular EC-EC gaps (PϽ0.01; Figure 1E ). The presence of microvascular EC-EC gaps during cold and warm ischemia was confirmed by fluorescence microscopy of grafts that received intracoronary perfusion of endothelium-binding rhodamine-labeled Concavalin A lectin and basement membrane-binding biotinlabeled R. communis lectin 22 ( Figure 1F ).
Donor Simvastatin Treatment Prevents Microvascular RhoA/ROCK Activation and Endothelial Cell-Endothelial Cell Gap Formation During Cold and Warm Ischemia
Next, we investigated whether peroral donor treatment with simvastatin 5 mg/kg 2 hours before graft procurement inhibits graft RhoA/ROCK activation and EC-EC gap formation.
Simvastatin was absorbed and metabolized to its active form in hours in rats (simvastatin 5 mg/kg; Figure IA in the online-only Data Supplement) and in human organ donors (simvastatin 80 mg; Figure IB in the online-only Data Supplement). Donor simvastatin treatment decreased p-adducin immunoreactivity in capillaries (PϽ0.05; Figure  1B ), postcapillary venules, and arterioles (PϽ0.05; Figure  1C ), as well as in the media of arteries (PϽ0.05; Figure 1D ), and decreased the formation of EC-EC gaps (PϽ0.001; Figure 1E and 1F), indicating decreased RhoA/ROCK activation and enhanced endothelial stability.
Donor Simvastatin Treatment Decreases Hypoxia-Inducible Factor-1␣, Inducible Nitric Oxide Synthase, and Endothelin-1 and Increases Heme Oxygenase-1 mRNA During Cold and Warm Ischemia
Real-time reverse-transcription polymerase chain reaction analysis showed that 4-hour cold and 1-hour warm ischemia significantly decreased inducible NOS (iNOS) (PϽ0.01; Figure 2A ), vascular endothelial growth factor (PϽ0.001; Figure 2A ), and HO-1 (PϽ0.05; Figure 2B ) mRNA levels, whereas it increased heat shock protein 27 mRNA levels (PϽ0.05; Figure 2B ) in the rat heart. Donor simvastatin treatment significantly decreased mRNA levels of hypoxiainducible factor-1␣ (HIF-1␣; PϽ0.05; Figure 2A ), its downstream iNOS (PϽ0.05; Figure 2A ), and vasoconstrictive endothelin-1 (PϽ0.05; Figure 2B ) and increased the expression of protective HO-1 (PϽ0.05; Figure 2B ). Simvastatin treatment resulted in a 50% reduction in EC HIF-1␣ and endothelin-1 mRNA levels in vitro ( Table I in 
Cold and Warm Ischemia Induce Vascular Leakage, the No-Reflow Phenomenon, and Myocardial Edema During Reperfusion
To determine the effect of allograft reperfusion on microvascular permeability and perfusion, DA hearts with or without 4-hour cold ischemia were transplanted to Wistar Furth recipients using a standardized 1-hour warm ischemia. In a vascular permeability assay, 4-hour cold ischemia significantly increased Evans blue dye extravasation 30 minutes after reperfusion (PϽ0.001; Figure 3A ). This was accompanied by a prominent no-reflow phenomenon with diminished numbers of perfused capillaries determined by intracoronary injection of endothelium-binding FITC-labeled L. esculentum lectin 30 minutes after reperfusion (PϽ0.01; Figure 3B ). The loss of microvascular perfusion was not due to widespread intravascular thrombosis ( Figure II in the online-only Data Supplement). Furthermore, serial laser Doppler measurements from the apex of normal DA hearts and cardiac allografts with 4-hour cold ischemia ( Figure 3C ) showed a prominently diminished microvascular perfusion early after cardiac allograft reperfusion (15 mL ⅐ min Ϫ1 ⅐ 100 g Ϫ1 tissue 1 to 30 minutes after reperfusion) that gradually increased (30 mL ⅐ min Ϫ1 ⅐ 100 g Ϫ1 tissue 1 hour after reperfusion) toward normal DA heart values (53Ϯ0.7 mL ⅐ min Ϫ1 ⅐ 100 g Ϫ1 tissue), indicating that IRI results in impaired microvascular perfusion early after reperfusion that gradually resolves over time.
To assess myocardial edema, we used cardiac allograft magnetic resonance imaging to analyze myocardial transverse relaxation time (T2) value 4 hours after reperfusion. T2 Ͼ40 milliseconds is considered an indicator of edema. 5 The T2 median value of normal DA hearts was 32 milliseconds ( Figure 3D , dashed line), whereas that of cardiac allografts with 4-hour cold ischemia was 55 milliseconds, indicating myocardial edema ( Figure 3D ).
Donor Simvastatin Treatment Prevents Vascular Leakage, the No-Reflow Phenomenon, and Myocardial Edema in During Reperfusion
To investigate the effect of donor simvastatin treatment on microvascular dysfunction, donor DA rats were given simva- statin 5 mg/kg via a nasogastric tube 2 hours before allograft removal. Donor simvastatin treatment prevented Evans blue dye extravasation (PϽ0.001; Figure 3A ), maintained normal myocardial capillary perfusion 30 minutes after reperfusion (PϽ0.01; Figure 3B ), resulted in rapid restoration of microvascular perfusion to normal levels as early as 1 minute after reperfusion (PϽ0.001; Figure 3C ), and led to normal myocardial T2 values 4 hours after reperfusion (PϽ0.05; Figure  3D ). These results indicate that donor simvastatin treatment offers immediate and profound microvasculature protection after cardiac allograft reperfusion.
Donor But Not Recipient Simvastatin Treatment Prevents Ischemia/Reperfusion Injury
We next treated the donor (5 mg/kg), the recipient (2 mg/kg), or both with simvastatin. Six hours after reperfusion, the 4-hour cold ischemia increased serum cardiac troponin T levels (PϽ0.01; Figure 4A ) and the number of allograft-infiltrating ED-1 ϩ macrophages (PϽ0.05; Figure 4B ) and myeloperoxidase ϩ neutrophils (PϽ0.01; Figure 4B ) compared with allografts without 4-hour cold ischemia. Donor simvastatin treatment and combined donor and recipient simvastatin treatment decreased serum cardiac troponin T levels (PϽ0.05, PϽ0.01; Figure 4A ) and the number of allograft-infiltrating ED1 ϩ macrophages (PϽ0.01, PϽ0.05; Figure 4B ) and myeloperoxidase ϩ neutrophils (PϽ0.05, PϽ0.01; Figure 4B 27 (PϽ0.05; Figure 4D ) and decreased dendritic cell maturation marker CD86 mRNA levels (PϽ0.001; Figure IVC in the online-only Data Supplement). In addition, combined donor and recipient treatment significantly decreased allograft mRNA levels of profibrotic basic fibroblast growth factor and TGF-␤1 (PϽ0.05; Figure 4D ), vasoconstrictive endothelin-1 (PϽ0.05; Figure 4D ), and hyaluronan synthase-1 (PϽ0.01; Figure IVA in the online-only Data Supplement). In addition, donor and combined donor and recipient simvastatin treatment significantly decreased allograft nuclear HIF-1 immunoreactivity (PϽ0.01; Figure V in the online-only Data Supplement).
Beneficial Effects of Donor Simvastatin Treatment on Microvasculature Stability and Perfusion Are Mediated Through Nitric Oxide and RhoA During Ischemia/Reperfusion Injury
We next investigated whether endothelial NOS, 23 HO-1, 24 and RhoA activation through prenylation 25 mediated the protective effects of simvastatin. Inhibition of NOS by donor L-NAME administration reversed the antipermeabil-ity (PϽ0.01; Figure 5A ) and antiinflammatory (PϽ0.05; Figure 5D and 5E) effects achieved with donor simvastatin treatment. Inhibition of HO-1 by donor zinc protoporphyrin administration did not result in significant changes in permeability, inflammation, or serum troponin T levels ( Figure 5A through 5D ). Supplementation of RhoA GT-Pase prenylation pathway by concomitant geranylgeranyl pyrophosphate reversed the beneficial effects of donor simvastatin treatment on capillary perfusion (PϽ0.05; Figure 5B and 5F). These results indicate that NO and the RhoA prenylation pathway participate in microvascular stability and perfusion after donor simvastatin treatment, respectively.
Donor Simvastatin Treatment Has Sustained Antiinflammatory Effects in Immunosuppressed Rat Cardiac Allografts
We next investigated the effect of donor, recipient, and both donor and recipient simvastatin treatment on cardiac allograft inflammation 10 days after transplantation in cyclosporine A-immunosuppressed recipients. In the re- 
Donor Simvastatin Treatment Decreases Cardiac Allograft Fibroproliferative Activity and Transforming Growth Factor-␤1 Signaling
Because inflammation and TGF-␤1 signaling play a pathological role in myocardial fibrosis, 26 cardiac allografts were stained with fibroblast marker prolyl-4-hydroxylase and phosphorylated Smad2 (p-Smad2), which indicates TGF-␤1 activation. At 10 days after transplantation, numerous prolyl-4-hydroxylase ϩ fibroblasts ( Figure 7A ) and p-Smad2 ϩ cells ( Figure 7B) were present in the border zone of fibrotic areas in allografts. Simvastatin treatment of donors and both donors and recipients decreased the number of allograft prolyl-4hydroxylase ϩ fibroblasts (PϽ0.05, PϽ0.01; Figure 7A ). Donor simvastatin treatment significantly decreased the number of allograft p-Smad2 ϩ cells (PϽ0.01; Figure 7B ). These results indicate that donor simvastatin treatment has sustained effects on allograft TGF-␤1 signaling and initiation of fibrotic pathways.
Simvastatin Decreases Transforming Growth Factor-␤1-Induced Endothelial-to-Mesenchymal Transition of Human Cardiac Microvascular Endothelial Cells
We next investigated whether simvastatin interferes with TGF-␤1-induced EndMT by stimulating cultured human cardiac microvascular ECs with TGF-␤1 in the presence of different concentrations of simvastatin. Indeed, TGF-␤1 induced a clear morphological change characterized by human cardiac microvascular EC filopodia formation and loss of cell-to-cell contact at 3 days. In addition, the tight junction protein zonula occludens-1 was clearly lost from EC surfaces ( Figure 7C ). In addition, TGF-␤1 markedly increased mRNA levels of mesenchymal genes calponin and ␣-SMA ( Figure  7D ), as well as calponin protein levels, at 6 days ( Figure 7E ), indicating EndMT. Simvastatin inhibited human cardiac microvascular EC filopodia formation, cell detachment, and relocation of zonula occludens-1 induced by TGF-␤1 ( Figure 7C) , and a concentration-dependent reduction was noted in the human cardiac microvascular EC calponin (R 2 ϭ0.751, Pϭ0.005; Figure 7D ) and ␣-SMA (R 2 ϭ0.623, Pϭ0.020; Figure 7D ) mRNA levels and calponin protein levels ( Figure 7E ). These findings indicate that inhibition of EndMT may directly contribute to the antifibrotic effects of simvastatin.
Treatment of Both Donor and Recipient With Simvastatin Has Beneficial Effects on Long-Term Survival and the Development of Cardiac Allograft Fibrosis and Arteriosclerosis
Next, we investigated the long-term effects of simvastatin treatment on cardiac allograft inflammation, survival, capillary density, fibrosis, and arteriosclerosis using a chronic rejection model with cyclosporine A background immunosuppression. Because our preliminary studies indicated that the 4-hour cold ischemia resulted in poor 56-day allograft survival (Ϸ30%), the grafts were subjected to 2-hour cold ischemia.
At 56 days, the 2-hour cold ischemia increased allograft CD4 ϩ T-cell density (PϽ0.05; Figure 8A ), reduced cardiac allograft survival from 86% (54Ϯ2 days) to 44% (47Ϯ4 days; Figure 8B ), decreased myocardial RECA-1 ϩ capillary density (PϽ0.05; Figure 8C ), and enhanced cardiac allograft arteriosclerosis (PϽ0.05; Figure 8G ) compared with allografts without the 2-hour cold ischemia. Donor and combined donor and recipient simvastatin treatment decreased the number of allograft-infiltrating ED1 ϩ macrophages, myeloperoxidase ϩ neutrophils, and CD4 ϩ T cells (PϽ0.05; Figure 8A and Figure VI in the online-only Data Supplement) and reduced myocardial fibrosis (PϽ0.05; Figure 8E and 8F). Treatment of both donors and recipients with simvastatin also significantly prolonged cardiac allograft survival (PϽ0.05; Figure 8B ), increased RECA-1 ϩ capillary density (PϽ0.01; Figure 8C and 8D), and reduced cardiac allograft arteriosclerosis (PϽ0.05; Figure 8G and 8H). Our findings thus indicate that combining the beneficial early effects of donor simvastatin treatment with daily recipient simvastatin treatment gives the best long-term protection for cardiac allografts.
Discussion
Similar to the response-to-injury hypothesis on atherosclerosis, 27 our present findings highlight the importance of early injury to cardiac allografts in the development of subsequent pathological responses. A clinically relevant 4-hour cold ischemia followed by 1-hour warm ischemia increased allograft cardiomyocyte injury and inflammation 6 hours after reperfusion of cardiac allografts. This early injury had sustained effects on the development of chronic rejection, as shown in previous experimental transplantation studies. 28 Interestingly, cold and warm ischemia resulted in cardiac allograft microvascular RhoA/ROCK activation and formation of EC-EC gaps and led to profound microvascular permeability and the no-reflow phenomenon after reestablishment of circulation. Thus, our findings support the critical role of microvascular injury and dysfunction in cardiac allograft IRI 4, 15 and in the development of chronic rejection. 2, 7 It is important that administration of a single dose of simvastatin to cardiac allograft donors prevented IRI and had beneficial long-term consequences (main findings of the study are summarized in the Table) . The rapid effects of peroral administration of simvastatin to the allograft donor only 2 hours before graft removal may have important implications because this time frame fits the window of organ donor treatment in clinical transplantation and makes benchto-bedside studies feasible. The short-term effects of statins are supported by previous clinical observations on the beneficial effects of peroral statin administration hours before percutaneous coronary intervention, 29 although most studies reporting IRI protection are performed with long-term statin administration for days, weeks, or months before IRI. 25, 30, 31 A multitude of evidence in our study indicates that the protective effects of donor simvastatin treatment on microvasculature were cholesterol-independent pleiotropic effects. First, the cholesterol levels of rats were low with a low-cholesterol diet, and the levels were not affected by simvastatin treatment (see Results in the online-only Data Supplement). Second, HMG-CoA reductase expression was detected mainly in cardiac microvasculature. Third, donor, but not recipient, simvastatin treatment effectively blunted the IRI. Fourth, donor simvastatin treatment resulted in beneficial microvascular effects in that it stabilized the endothelium during allograft preservation and reversed the profound microvascular EC permeability and the no-reflow phenomenon after reperfusion. Fifth, simvastatin prevented microvascular RhoA/ROCK activation, the pathway considered central in the pleiotropic effects of statins 16 in both experimental [32] [33] [34] [35] and clinical studies. 17, 36 In addition to microvascular ECs, the surrounding pericytes have an important regulatory role in physiological and pathological microvascular functions. 12 Our present results suggest that simvastatin controls vascular permeability and the no-reflow phenomenon in cardiac allograft IRI by regulating microvascular EC integrity and pericyte contraction, respectively. Inhibition of NOS with L-NAME reversed the beneficial effect of donor simvastatin treatment on vascular permeability but had no effect on capillary perfusion. This supports the role of simvastatin and endothelial NOS in the regulation of endothelial integrity 37 and indicates that the no-reflow phenomenon in our study was not due to edemainduced capillary collapse. In addition, the lack of intravascular thrombosis in the cardiac allografts suggests that there must be additional mechanisms behind the observed myocardial perfusion defects. Interestingly, HMG-CoA reductase was expressed in microvascular pericytes, and supplementation of the geranylgeranyl pyrophosphate pathway, which is important for RhoA activation, 16, 25 recapitulated the noreflow phenomenon. Previous studies show that sustained microvascular pericyte contraction impairs capillary reflow after cerebral ischemia 15 and that RhoA modulates the contractile phenotype of pericytes. 13, 14 Thus, our results present the novel possibility that statins control the no-reflow phenomenon through regulation of pericyte contraction. Importantly, we also found that donor simvastatin treatment increased cardiac allograft HO-1 and heat shock protein 27 expression, which may also participate in the protective effects of statins in IRI. 24, 38 Interestingly, we found that simvastatin decreased the mRNA levels of HIF-1␣ in rat hearts. Previously, statins have been shown to decrease HIF-1␣ DNA binding in ECs and smooth muscle cells 39 and HIF-1␣ immunoreactivity in pig arteries. 40 However, to the best of our knowledge, this is the first study to show that simvastatin decreases HIF-1␣ mRNA. RhoA indicates ras homolog gene family member A; EC, endothelial cell; HIF-1␣, hypoxia-inducible factor-1␣; iNOS, inducible nitric oxide synthase; ET-1, endothelin-1; HO-1, heme oxygenase-1; HSP27, heat shock protein 27; VCAM-1, vascular cell adhesion molecule-1; TGF-␤1, transforming growth factor-␤1; EndMT, endothelial-to-mesenchymal transition; and HMVEC, human cardiac microvascular endothelial cell.
Mechanistically, these effects may be attributed to RhoA inhibition by simvastatin because RhoA regulates HIF-1␣ mRNA expression in renal cell carcinoma 41 and trophoblast cells. 42 Recent observations show that ECs contribute directly to myocardial fibrosis in a process of EndMT. 11 A similar phenomenon, epithelial-to-mesenchymal transition, occurs in kidney fibrosis; it involves TGF-␤1, 43 RhoA, 44 hypoxia, and HIF-1 45 and is inhibited by statins. 44 Here, we found that donor simvastatin treatment reduced cardiac allograft TGF-␤1 activation and fibrosis and that simvastatin also inhibited TGF-␤1-induced EndMT in vitro. Our results thus support the findings that cardiac allograft EC dysfunction may directly participate in myocardial fibrosis through EndMT. 11 In addition, our novel finding that simvastatin inhibits EndMT may have important consequences for the treatment of myocardial fibrosis in both cardiac allografts and nontransplant situations.
Conclusions
Our results demonstrate that donor simvastatin treatment has beneficial molecular and functional effects on microvascular ECs and pericytes and may be used to counteract early microvascular dysfunction and the initiation of fibroproliferative pathways during IRI in cardiac allografts. Our results thus suggest a novel, clinically feasible strategy to protect cardiac allografts.
